Sermonix Announces Clinical Breast Cancer Publication of Article Examining Effects of Lasofoxifene Versus Fulvestrant on Urogenital Symptoms in Patients with ESR1-Mutated ER+/HER2- Metastatic Breast Cancer

by | Jan 29, 2025 | News

Lasofoxifene, but not fulvestrant, improved vaginal and vulvar symptoms in quality of life secondary endpoint analysis   COLUMBUS, Ohio, Jan. 29, 2025 (GLOBE NEWSWIRE) — Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing...